Actively Recruiting
Testing the AQUAPASS Device to Reduce Fluid Overload in Heart Failure Patients Using a Non-Invasive, Renal Independent System
Led by AquaPass Medical Ltd. · Updated on 2026-11-02
40
Participants Needed
10
Research Sites
36 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the AQUAPASS system, a new wearable device designed to help remove excess fluid through sweat in patients with decompensated heart failure and chronic kidney disease stage 2-3. The study aims to test whether AQUAPASS can safely and effectively reduce fluid overload in patients who are not responding well to current medical treatments such as diuretics. The trial compares fluid removal using AQUAPASS combined with usual medications to standard treatment alone. Participants will undergo treatment sessions of up to 5 hours wearing the AQUAPASS lightweight suit, supervised by trained staff. The trial uses a crossover design where patients receive both the AQUAPASS treatment and an observation period without the device to compare results. Fluid removal effectiveness will be measured by changes in body weight and fluid balance, while blood and urine tests will monitor kidney and heart function. During the study, participants will have daily assessments including body weight measurements, congestion scores, and blood and urine tests to monitor safety and kidney performance. The primary outcome is the evaluation of AQUAPASS performance over 5 days, with safety monitored over 6 hours. The study takes place in hospital or outpatient clinic settings, and participant involvement includes both treatment and observation visits. The total study duration extends until April 2027.
CONDITIONS
Brief Title
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
Research Team
S
Scott C Feitell, DO
J
Julie Mooney, RN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here